Presentation is loading. Please wait.

Presentation is loading. Please wait.

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Published bySabina Fowler Modified over 5 years ago

Similar presentations

Presentation on theme: "Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P"— Presentation transcript:

1 Unexpectedly Fludeoxyglucose (18F) Avid Well-Differentiated Adenocarcinoma of the Lung 
Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P. Holland, PA, Tobias Peikert, MD, Geoffrey B Johnson, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 4, Pages (April 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 ** Fig.1. A, Non-contrast CT shows a ground glass pulmonary nodule. B-D, FDG-PET CT 1-month after the initial CT shows the nodule to be intensely FDG avid. Four-month follow-up non-contrast CT shows no change in the appearance of the nodule (E), and the nodule remained FDG avid at 4 months (F). G and H, surgical specimen reveals a well differentiated adenocarcinoma with a lepidic growth pattern. I, CT scan 6 years prior to the patient's initial presentation shows an 11mm faint pure GGN suggesting very slow interval growth. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment  Tjeerd S. Aukema, MD, Renato.

Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment  Tjeerd S. Aukema, MD, Renato.
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Fig. 6. A 56-year-old man with lepidic predominant invasive adenocarcinoma (LPA). A. Initial transverse 2.5 mm thin-section CT scan shows 14 mm pure ground-glass.

Fig. 6. A 56-year-old man with lepidic predominant invasive adenocarcinoma (LPA). A. Initial transverse 2.5 mm thin-section CT scan shows 14 mm pure ground-glass.
Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.

Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802)

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )
Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1 

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1 

Similar presentations

Ads by Google